CLINICAL OUTCOMES OF GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE — A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES
The International Journal of Medical Science and Health Research · 19.11.2026 · 49 (3) · 1023-1109
DOI: 10.70070/swg94g76 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 19.11.2026. Verfasst von Angga Rifqi Mujidiatama und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Older adults carry the largest absolute burden of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), yet they are under-represented in cardiovascular outcome trials (CVOTs), and clinicians remain uncertain whether the cardiorenal benefits of contemporary glucose-lowering drugs persist, attenuate or amplify with advancing age. We aimed to quantify the excess risk of adverse clinical outcomes conferred by older age in patients with T2DM and CVD, and to synthesise the efficacy and safety of sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) specifically in geriatric patients.
Methods
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. PubMed, Europe PMC, Semantic Scholar and ClinicalTrials.gov were searched for reports published between 16 November 2011 and 16 November 2026, supplemented by citation searching. Randomised controlled trials (RCTs) reporting age-stratified outcomes (≥65 or ≥75 years), comparative cohort studies and case series in older adults were eligible; systematic reviews were reserved for the discussion. Risk of bias was assessed with RoB 2 and ROBINS-I. Hazard ratios (HRs) were pooled with DerSimonian–Laird random-effects models, with Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment and 95% prediction intervals. Effect modification by age was quantified as within-trial ratios of HRs, and prognosis as control-arm risk ratios (RRs) for older versus younger participants. Certainty of evidence was graded with GRADE.
Results
Nineteen studies were included: 10 age-stratified analyses representing 11 CVOTs (105,752 randomised participants; 43,692 aged ≥65 years and 10,172 aged ≥75 years) and 9 cohort studies (approximately 1.43 million analysed patient records aged ≥65 years). In control arms, older age was associated with higher risks of major adverse cardiovascular events (MACE; RR 1.58, 95% CI 1.38–1.81), all-cause death (RR 2.03, 1.61–2.57), hospitalisation for heart failure (HHF; RR 1.88, 1.56–2.26) and severe hypoglycaemia (RR 1.54, 1.25–1.90). Versus placebo, glucose-lowering therapy reduced MACE in patients aged ≥65 years (HR 0.90, 0.82–0.98; k = 9; I² = 50%), driven by GLP-1RA (HR 0.85, 0.76–0.94) with directionally favourable SGLT2i (HR 0.90, 0.74–1.08) and neutral DPP-4i (HR 1.02, 0.89–1.16). In patients aged ≥75 years, MACE (HR 0.82, 0.70–0.97) and cardiovascular death (HR 0.67, 0.51–0.87) were reduced. HHF was reduced (HR 0.85, 0.74–0.97; I² = 1%), whereas all-cause death (HR 0.94, 0.79–1.11) and severe hypoglycaemia (HR 0.84, 0.65–1.09) were not significantly changed. The ratio of HRs for MACE in older versus younger participants was 0.98 (0.85–1.13), indicating no attenuation of relative benefit with age. In cohorts, SGLT2i versus DPP-4i was associated with lower all-cause mortality (HR 0.68, 0.58–0.81) and MACE (HR 0.72, 0.61–0.84) but heterogeneous HHF effects (HR 0.77, 0.56–1.06; I² = 98%) and more genital infections (HR 2.04, 1.43–2.91); GLP-1RA versus DPP-4i was associated with lower MACE (HR 0.76, 0.67–0.85), and SGLT2i versus GLP-1RA with lower HHF (HR 0.73, 0.67–0.81). Because baseline risk is high, approximately 32 MACE (NNT 31) and 38 cardiovascular deaths (NNT 27) could be prevented per 1000 patients aged ≥75 years treated over 2–5 years.
Discussion
Advancing age amplifies the absolute cardiovascular, heart-failure and hypoglycaemic risk of patients with T2DM and CVD, whereas the relative benefit of cardioprotective glucose-lowering drugs is preserved. The combination of an age-invariant relative risk reduction with a steep, age-dependent baseline risk translates into greater absolute benefit in the oldest patients. Real-world data extend these signals to octogenarians but are limited by residual confounding and heterogeneity.
Conclusion
Geriatric patients with T2DM and CVD have markedly worse clinical outcomes than younger patients but derive at least equivalent relative, and larger absolute, benefit from GLP-1RA and SGLT2i. Chronological age alone should not preclude cardioprotective therapy; treatment should be individualised through comprehensive geriatric assessment, and dedicated trials in frail and very old adults are needed.
Zitieren
APA
Mujidiatama, A. R., Ilyas, A. A., Molandro, T. I., Wahyuni, D. O., & Ahmad, F. F. (2026). CLINICAL OUTCOMES OF GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE — A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research, 49(3), 1023-1109. https://doi.org/10.70070/swg94g76
Vancouver
Mujidiatama AR, Ilyas AA, Molandro TI, Wahyuni DO, Ahmad FF. CLINICAL OUTCOMES OF GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE — A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research. 2026;49(3):1023-1109. doi:10.70070/swg94g76
BibTeX
@article{Mujidiatama2026,
author = {Mujidiatama, Angga Rifqi and Ilyas, Amirsyani Ariestotama and Molandro, Theodore Isaac and Wahyuni, Diona Ossy and Ahmad, Fery Fandi},
title = {CLINICAL OUTCOMES OF GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE — A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES},
journal = {The International Journal of Medical Science and Health Research},
year = {2026},
volume = {49},
number = {3},
pages = {1023--1109},
doi = {10.70070/swg94g76}
}
EUVIMED